Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study come back negative or a candidate not be approved. Conversely, if a drug gains FDA approval or passes a clinical trial, there can be big upside.
The White House has promised reforms in the health care sector, such as changing the bidding process for drugs and shortening the FDA approval process. It is yet to be seen how much headway they can actually make with these reforms.
Keep in mind that short sellers betting against big pharma are taking on an added risk. They have to pay out the ongoing high dividends on top of the cost of borrowing the shares.
The June 29 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
Short interest in Pfizer Inc. (NYSE: PFE) decreased to 59.17 million shares from the previous 64.69 million. The stock was last seen trading at $37.21, within a 52-week range of $32.32 to $39.43.
The number of Merck & Co. Inc. (NYSE: MRK) shares short decreased to 17.15 million from 21.87 million in the previous period. Its shares were trading at $61.90, in a 52-week range of $52.83 to $66.41.
Teva Pharmaceutical Industries Ltd.’s (NYSE: TEVA) short interest decreased to 44.39 million from the previous level of 47.70 million. Shares were trading at $23.75, in a 52-week range of $10.85 to $33.82.
Bristol-Myers Squibb Co. (NYSE: BMY) short interest increased to 14.69 million shares from the previous reading of 14.50 million. Shares were last seen at $55.75, in a 52-week range of $49.96 to $70.05.
The number of shares short in AbbVie Inc. (NYSE: ABBV) decreased to 33.27 million from the previous 38.44 million. The stock was trading at $94.96, and its 52-week range is $69.38 to $125.86.
Eli Lilly and Co.’s (NYSE: LLY) short interest decreased to 11.49 million shares from the previous 12.81 million. The stock was trading at $87.56. The 52-week range is $73.69 to $89.09.
24/7 Wall St.Cash Back Credit Cards Have Never Been This Good
Credit card companies are at war, handing out free rewards and benefits to win the best customers. A good cash back card can be worth thousands of dollars a year in free money, not to mention other perks like travel, insurance, and access to fancy lounges. See our top picks for the best credit cards today. You won’t want to miss some of these offers.
Flywheel Publishing has partnered with CardRatings for our coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
